- Home
- INSM vs PHM Comparison
INSM vs PHM Comparison
Compare INSM & PHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- PHM
- Stock Information
- Founded
- INSM 1988
- PHM 1950
- Country
- INSM United States
- PHM United States
- Employees
- INSM N/A
- PHM N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- PHM Homebuilding
- Sector
- INSM Health Care
- PHM Consumer Discretionary
- Exchange
- INSM Nasdaq
- PHM Nasdaq
- Market Cap
- INSM 26.0B
- PHM 22.8B
- IPO Year
- INSM 2000
- PHM N/A
- Fundamental
- Price
- INSM $127.80
- PHM $128.67
- Analyst Decision
- INSM Strong Buy
- PHM Buy
- Analyst Count
- INSM 17
- PHM 15
- Target Price
- INSM $137.40
- PHM $135.64
- AVG Volume (30 Days)
- INSM 3.0M
- PHM 2.1M
- Earning Date
- INSM 08-07-2025
- PHM 07-22-2025
- Dividend Yield
- INSM N/A
- PHM 0.68%
- EPS Growth
- INSM N/A
- PHM 2.26
- EPS
- INSM N/A
- PHM 13.40
- Revenue
- INSM $398,105,000.00
- PHM $17,694,541,000.00
- Revenue This Year
- INSM $28.23
- PHM N/A
- Revenue Next Year
- INSM $119.99
- PHM $0.07
- P/E Ratio
- INSM N/A
- PHM $9.61
- Revenue Growth
- INSM 21.15
- PHM 5.04
- 52 Week Low
- INSM $60.40
- PHM $88.07
- 52 Week High
- INSM $128.48
- PHM $149.47
- Technical
- Relative Strength Index (RSI)
- INSM 85.01
- PHM 69.68
- Support Level
- INSM $106.54
- PHM $118.36
- Resistance Level
- INSM $128.48
- PHM $131.08
- Average True Range (ATR)
- INSM 4.11
- PHM 3.42
- MACD
- INSM 1.68
- PHM 0.83
- Stochastic Oscillator
- INSM 97.41
- PHM 86.30
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.